secwatch.observer — SEC 8-K summary
======================================

Issuer:     Syndax Pharmaceuticals Inc (SNDX)
CIK:        0001395937
Form:       8-K
Filed at:   2025-05-05T23:59:59+00:00
Accession:  0000950170-25-063514
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Syndax Q1 Revuforj rev $20M, Niktimvo rev $13.6M; sNDA for mNPM1 AML
--------------------------------------------------------------------

- Revuforj net revenue $20.0M in first full quarter; Niktimvo net revenue $13.6M (Incyte reported) in first partial quarter.
- Submitted sNDA seeking Priority Review for revumenib in R/R mNPM1 AML under FDA RTOR program.
- Initiated EVOLVE-2 pivotal frontline trial of revumenib + venetoclax/azacitidine in mNPM1 and KMT2Ar AML.
- Net loss $84.8M ($0.98 per share) vs $72.4M ($0.85 per share) year ago; cash $602.1M.
- Full-year 2025 R&D guidance $260-280M, total R&D+SG&A $415-435M; expects to reach profitability.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1395937/000095017025063514/0000950170-25-063514-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1395937/000095017025063514/sndx-20250505.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-063514

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer